Treatment of Hepatocellular Carcinoma Smaller than 5 CM by Transcatheter Arterial Chemoembolization

小型肝細胞癌的經導管動脈化學栓塞術

謝明裕(Ming-Yuh Hsieh) ； 陳信成(Shinn-Cherng Chen) ； 盧勝男(Sheng-Nan Lu) ； 王良彥(Liang-Yen Wang) ； 蔡榮發(Jung-Fa Tsai) ； 莊萬龍(Wan-Long Chuang) ； 林子堯(Zu-Yau Lin) ； 張文宇(Wen-Yu Chang)

《The Kaohsiung Journal of Medical Sciences》 12卷5期 (1996/05) Pp. 274-278

https://doi.org/10.6452/KJMS.199605.0274

摘要

為了評估經導管動脈化學栓塞術對於小型肝細胞癌的療效並分析其預後因素，我們選取77例經組織學證實，小於5公分的肝細胞癌患者接受治療同時至少追蹤超過兩年，結果其1 年、2 年、3年之存活率分別為79.2%、50.6%及36.7%。Pugh ‘s A病人的平均存活率為990±146天比Pugh’s B病人的450±52天為佳，另外HBeAg陽性以及胎兒蛋白升高病人預後則較差。至於性別、年齡、HBsAg、Anti-HCV、腫瘤大小及腫瘤數目則與本療法之預後無關。

並列摘要

To assess the effectiveness of transcatheter arterial chemoembolization (TACE) in the treatment of small hepatocellular carcinoma (HCC) and to analyze the prognostic factors, a total of 77 patients with histologically proven HCC, ≦5 cm in diameter, were enrolled for the study and followed for more than 2 years, The overall cumulative 1-, 2-, and 3-year survival rates were 79.2%, 50.6% and 36.7%, respectively.
The median survival time of Child-Pugh’s A patients was 990±146 days, which was significantly better than the median survival time of Child-Pugh’s B patients (450±82 days) Furthermore, positive HBeAg andα-Fetoprotein (AFP) were factors close to statistically significant. In contrast, sex, age, HBsAg, Anti-HCV, tumor type, tumor size and tumor number were not related to the prognosis in small HCC who received TACE.

並列關鍵字

α-fetoprotein ； hepatocellular carcinoma ； transcatheter arterial chemoe-mbolization